Sai Life Sciences (SAILIFE) investor relations material

Executive summary

• FY26 saw revenue growth of 29%, EBITDA up 56%, and PAT up 109% year-over-year, driven by both CRO and CDMO segments and deepened global pharma relationships, positioning the company for innovation-led outsourcing opportunities.

• Large pharma clients now contribute 49% of revenue, up from 28% in FY22, reflecting deepening strategic relationships.

• The company works with 19 of the top 25 global pharma companies and has a pipeline of 34 commercial molecules, 11 in phase III/pre-registration, and 155 in earlier stages.

• Investments in automation, next-gen technologies (notably ADCs), and digital/AI transformation are central to the growth strategy.

• Audited standalone and consolidated financial results for FY26 and Q4FY26 were approved, with unmodified opinions from auditors.

Financial highlights

• FY26 consolidated revenue reached ₹2,192 Cr (Rs. 21,924.92 million), up 29% year-over-year from ₹1,695 Cr (Rs. 16,945.70 million) in FY25.

• EBITDA rose 56% to ₹661 Cr, with margin expanding by 508 bps to 30% due to operating leverage.

• PAT before exceptional items increased 109% to ₹355 Cr (consolidated net profit Rs. 3,489.10 million), compared to ₹170 Cr (Rs. 1,701.32 million) in FY25.

• CDMO revenue grew 33% to ₹1,417 Cr; CRO revenue grew 24% to ₹775 Cr.

• Revenue split between H1 and H2 was 48% and 52%, showing more even distribution than prior years.

Outlook and guidance

• Targeting 15%-20% annual revenue growth and maintaining EBITDA margins in the 28%-30% range over the next three years.

• CapEx for FY27 projected at INR 1,100-1,300 crores, with 65% for CDMO and 35% for CRO.

• Second half of FY27 expected to be stronger due to new capacities coming online.

• The company will continue to monitor and account for any further clarifications or impacts from the new Labour Codes in future periods.